Background: The European Organisation for Research and Treatment of Cancer (EORTC) Group has developed a new multidimensional instrument measuring cancer-related fatigue to be used in conjunction with the quality of life core questionnaire (EORTC QLQ-C30). The module EORTC QLQ-FA13 assesses physical, cognitive, and emotional aspects of cancer-related fatigue. Methods: The methodology follows the EORTC guidelines for phase IV validation of modules. This paper focuses on the results of the psychometric validation of the factorial structure of the module. For validation and cross-validation confirmatory factor analysis (maximum likelihood estimation), intraclass correlation and Cronbach alpha for internal consistency were employed. The study involved an international multicenter collaboration of 11 European and non-European countries. Results: A total of 946 patients with various tumor diagnoses were enrolled. Based on the confirmatory factor analysis, we could approve the three-dimensional structure of the module. Removing one item and reassigning the factorial mapping of another item resulted in the EORTC QLQ-FA12. For the revised scale, we found evidence supporting good local (indicator reliability ! 0.60, factor reliability ! 0.82) and global model fit (GFI t1jt2 ¼ 0.965/0.957, CFI t1jt2 ¼ 0.976/0.972, RMSEA t1jt2 ¼ 0.060/ 0.069) for both measurement points. For each scale, test-retest reliability proved to be very good (intraclass correlation: R t1-t2 ¼ 0.905-0.921) and internal consistency proved to be good to high (Cronbach alpha ¼ .79-.90).
Conclusion: Based on the former phase III module, the multidimensional structure was revised as a phase IV module (EORTC FA12) with an improved scale structure. For a comprehensive validation of the EORTC FA12, further aspects of convergent and divergent validity as well as sensitivity to change should be determined.
Fatigue is one of the most distressing symptoms for cancer patients, affecting their quality of life in all phases of the treatment or stages of the disease. Cancer-related fatigue (CrF) is commonly defined as a self-recognized phenomenon that is subjective in nature and experienced as a feeling of tiredness or lack of energy that varies in degree, frequency, and duration (1) . From a patient's perspective, fatigue is described as an unusual feeling of exhaustion, weakness, or a loss of activity with sequels to emotional and cognitive functions (2, 3) , which, in general, cannot be reduced by sleep or rest. Fatigue is the most frequent symptom occurring in cancer patients during or after medical treatment and also as a long-term late effect. Prevalence rates for CrF during or after the end of treatment range from 59% to 100%, whereas fatigue as a long-term sequelae or late effect is estimated to have an average prevalence rate of approximately 30% (dependent on the type of assessment and diagnostic criteria used) (4, 5, 6) . Because of an increased interest and research output in CrF, more detailed uni-or multidimensional instruments have been developed to assess CrF (7, 8) . These fatigue scales have different strengths and weaknesses, and there exist no robust recommendations describing which measure is the most appropriate. Using a standardized questionnaire allows clinicians to measure CrF in the course over time and allows comparisons between various patient subgroups. The EORTC QLQ-FA13 module has been developed following the methodological guidelines of EORTC, which include four phases of development: 1) generation of issues, 2) construction of items list, 3) pretesting, and 4) field testing (9) . The strengths of the questionnaires developed by the EORTC Quality of life Group lie in an international multicenter approach following high methodological standards and multicultural applicability. The pretested module EORTC QLQ-FA13 (phase III) is based on a multidimensional concept of fatigue including 13 items (11 items allocated to a physical, emotional, and cognitive domain and two single items on interference of CrF with daily activities and social sequelae of fatigue) (see Supplementary  Table 1 , available online). It has been designed to measure fatigue in conjunction with the quality of life core questionnaire EORTC QLQ-C30 (10) .
According to the EORTC Quality of Life Group guidelines (9), the purpose of phase IV of the module development is the evaluation of the psychometric characteristics and the validity of the EORTC QLQ-FA13 in an international sample of tumor patients. This paper focuses on the psychometric analysis of the scale structure of the EORTC QLQ-FA13 using confirmatory factor analyses. The main hypotheses for the factorial structure to be tested were the following: The factorial structure of the EORTC QLQ-FA13 phase III module should be replicated according to the underlying theory. The two single items (endogenic variables) FA12 ("Did fatigue interfere with your daily activities?") and FA13 ("Did you have the feeling that fatigue was not understood by people close to you?") were expected to be predicted adequately by the subscales physical, cognitive, and emotional fatigue. In addition, analyses of results on test-retest reliability and internal consistency are reported.
Methods

Design
The design for the psychometric evaluation of the EORTC QLQ-FA13 followed the guidelines of EORTC for the development of modules in phase IV. Patients were enrolled in four distinct groups (see Table 1 ): group A (curative) includes cancer patients receiving firstline treatment with curative intent (t1 A -t3 A ); group B (palliative) includes cancer patients receiving second-line treatment with palliative intent (t1 B -t3 B ); group C (survivor I) includes cancer patients off treatment (!12 and 18 months since end of treatment with no evidence of cancer The study was carried out as an international multicenter study including 17 centers in 11 European and non-European countries (Europe: England, France, Germany, Austria, Poland, Netherlands, Sweden, Spain, Italy; non-Europe: Egypt and Taiwan). For phase IV, the EORTC QLQ-FA13 has been translated to the languages of the cooperating countries. The translations were carried out in close cooperation with the translation team of the Quality of Life Department of EORTC following the translation guidelines of the EORTC QoL group (11) . We initially calculated a sample of 130 patients per group (over all groups, a total of n ¼ 520 patients) (12) . Because of higher dropout rates than expected, we increased recruitment and sample size up to the final sample of 946 patients. Patient recruitment was from February 2011 to November 2014. The study was registered with the German Clinical Trial Studies Registry (DRKS-ID: DRKS00003091). National and local ethics approvals were obtained for the recruiting centers before commencement of this study.
Inclusion and Exclusion Criteria
Patients with cancer of all tumor sites were included if they met the following criteria: histologically confirmed cancer, written informed consent, and the ability to understand the language of the questionnaire. Patients had to have an absence of severe psychiatric or cognitive mental conditions potentially hampering compliance with the study protocol and follow-up schedule, and all patients had to be older than age 18 years. Patients undergoing allogeneic hematological stem cell transplantation (HSCT) or neoadjuvant therapy were excluded. Patients could not participate in other quality of life studies that might interfere with this validation study.
Statistical Methods
Data entry, management, and statistical evaluation were conducted from the coordination center in Freiburg, Germany. Data analysis was done using SPSS v21, supported by a biostatistician who specializes in psychometric analyses. For the confirmatory factor analysis, Analysis of Moment Structures (AMOS), maximum likelihood method 21.0 was used. Missing values (<13) were replaced with stochastic regression-based imputation, available in AMOS 21.0 (13) . This estimation procedure uses information within the available data to avoid biases in the analyzed variance-covariance matrix. Hence, the analyzed information is not affected if data are missing because of missing-at-random processes (14) . The assumption of normal distribution was checked by the Mardia test in AMOS 21.0 and corrected in case of violation using the Bollen-Stine-Bootstrap strategy (15) . Item characteristics are described in terms of acceptance (percentage of responders), item discrimination (corrected item scale correlation), and item difficulty (mean score). Reliability was determined by the score for internal consistence (Cronbach's alpha) (15) . The a priori defined factor structure was checked by the discrepancy between the empirical based variance-covariance matrix and the variance-covariance matrix based on the model. For the evaluation of the model, indices of global and local fit were used. The chi-square test was used for the statistical testing of the model. Further indices for the goodness of fit were Root-Mean-Square-Error of Approximation (RMSEA) and Goodness of Fit Index (GFI) as absolute fit indices. Normed Fit Index (NFI), Tucker-Lewis Index (TLI), and Comparative Fit Index (CFI) were used as measures for incremental fit and the Adjusted Goodness of Fit Index (AGFI). RMSEA scores of less than 0.08 indicate an acceptable fit, scores of less than 0.05 a good model fit. Bootstrap statistics have been calculated for chi-square statistics and indicator reliabilities. For GFI, AGFI, NFI, TLI and CFI scores higher than 0.95 indicate a good model fit, scores higher than 0.90 an acceptable model fit (13) . For the estimation of the measurement models, local fit indices were calculated. For convergent validity, the indicator reliability should be greater than 0.4, factor reliability greater than 0.6, and DEV (mean variance) greater than 0.5 (16) . For univariate comparisons, we used t tests or the Tukey test, and for interpretation of the effect sizes we followed Cohen (1988;
For test-retest reliability, we used intraclass correlation with the data of groups C and D.
Except the chi-square test of global model fit, all statistical tests were two-sided. A P value of less than .05 was considered statistically significant.
Results
Description of the Sample
The total number of patients recruited in all groups was 946. The average age was 58.7 years (SD ¼ 13.1 years, range ¼ 22-97 years). Patients were recruited in Germany (16.1%) and Poland (15.6%), followed by the UK (11.1%), Sweden (10.0%), Egypt (9.9%), Spain (8.4%), the Netherlands (7.2%), Italy (5.0%), Austria (4.5%), and Taiwan (3.8%). Gender distribution was balanced (female ¼ 54.1 %, male ¼ 45.9%). The sample comprised of a wide spectrum of tumor diagnoses (for further details, see Table 2 ).
Confirmatory Factor Analysis
We use confirmatory factor analysis (CFA) to check the threefactorial model of the EORTC QLQ-FA13, including the t1 ABCD measurement of patients from all four groups (n ¼ 944) (Figure 1) . We used the two single items as indicators of the three latent constructs, as these two items do not underlie the latent construct but represent potential interference of CrF on activities of daily life and social functioning (Supplementary Table 1 , available online).
First, the check of normal distribution by the Mardia Test showed that the assumption of normally distributed data is moderately violated, but the analysis detected only slight deviation from this assumption, which is acceptable according to the recommendations in the literature (15, 16) . Nevertheless, we used the Bollen-Stine-Bootstrap strategy to correct the P score. The results of the CFA show that the underlying model of the EORTC QLQ-FA13 was not adequately reproduced by the data both for global (Table 3 ) and local fit indices ( Table 4) .
The indices in Table 3 show that the thresholds for acceptable model fit were not reached. The residual covariance suggests that item FA05 ("Did you have trouble getting things started?") is indicative of the physical domain (increase of factor loading from 0.70 to 0.77) (Figures 1 and 2 ). Item FA05 is more closely associated to the dimension of physical fatigue, which includes items of reduced physical functions and loss of performance. Therefore, the allocation of item FA05 from the cognitive to the physical dimension seems to be evident. Furthermore, item FA11 ("Did you have trouble completing things?") was insufficiently associated with the cognitive fatigue construct. Additionally, elimination of item FA11 caused considerable lower correlation between the latent construct in the model. The correlation between cognitive and emotional fatigue decreased from an r of 0.74 to and r of 0.58, as well as between cognitive and physical fatigue (from r ¼ 0.73 to 0.66). For the revised scale, we found evidence supporting good local (indicator reliability ! 0.60, factor reliability ! 0.82) and global model fit (GFI t1jt2 ¼ 0.965/0.957, CFI t1jt2 ¼ 0.976/0.972, RMSEA t1jt2 ¼ 0.060/0.069) for both measurement points. Hence, after deleting the hybrid item FA11 from the scale, the discriminability of the three constructs is noticeably enhanced and all fit indices and factor loadings (all ! 0.72) could be substantially improved, respectively.
In addition, we computed a model defining an overall fatigue construct as a second-order factor. The data basis for this model included all items of the three subscales (without the two single items FA11 and FA12). In this hierarchical model structure, the model fit is substantially lower (RMSEA ¼ 0.072) compared with the three-factorial model ( Table 3 ). Note that the three constructs predict the criteria FA12 and FA13 differently (Figure 2 ). For example, "cognitive" does not predict "F12" (-0.04), whereas "physical" is the major predictor of "F12" (0.78). These differential predictive weights of the exogenous fatigue construct contradict also the assumption of a second-order general fatigue factor. Hence, sample specific overfit cannot account for the differences between model estimates (Tables 3 and 4 ). In addition, the Bayesian Information criterion (BIC ¼ 424.521), taking model parsimony into account, indicates the three-factorial model structure to be most appropriate. 
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To check the stability and generalization of the structure equation model, a cross-validation of the results of the patients of all four groups at the time measurement t2 ABCD was conducted. The sample for cross-validation included 643 patients. The results of the cross-validation analysis show a slightly lower but still acceptable model fit (AGFI ¼ 0.921, RMSEA ¼ 0.070, CFI ¼ 0.970; indicator reliabilities from 0.52 to 0.81). Furthermore, the model estimations for the data of t2 ABCD or t3 AB confirmed the revised model for EORTC FA12 (Table 3) . Given these results, the structural equation model could be conclusively replicated both in the cross-validation sample and based on the t2 and t3 data, respectively. Furthermore, 500 bootstrap samples were drawn to analyze the stability of model fit.
For the chi-square statistics, a stable superiority of the modified model could be ascertained: The bootstrap distribution proved to be unimodal with a reasonable 95% confidence interval.
In terms of construct validity, patients with distant metastases had a statistically significantly higher score of overall fatigue than patients without distant metastases (M ARTICLE statistically significant correlation of the fatigue scores with the ECOG score for all subscales (physical fatigue: rs ¼ 0.481, P < .001; emotional fatigue: rs ¼ 0.322, P < .001; cognitive fatigue: rs ¼ 0.328, P < .001). Post hoc comparison of scores (Tukey test) showed that patients of the palliative group (group B) exhibited the highest fatigue scores compared with all other groups (MB ¼ 2.10, MA ¼ 1.75, MC ¼ 1.69, MD ¼ 1.67). In addition, there is a high negative correlation between fatigue in all subscales and the global quality of life (r ¼ À0.672, P < .001), showing that the higher the fatigue, the lower the global quality of life.
Test-Retest Reliability
Test-retest reliability was tested using the data of patients of the two survivor groups (survivor I and II, n ¼ 410). The time difference between t1 CD and t2 CD was an average of 9.3 days (SD ¼ 7.41). As the results of both subgroups were very similar, we report the results for both groups together. The correlations (intraclass correlation) for t1 CD and t2 CD in both groups show high scores for all three subdimensions, ranging from an r of 0.905 to an r of 0.921, indicating a high stability of measurement. In (Table 5 ).
Discussion
As part of a comprehensive psychometric validation of the EORTC FA13 module, we presented data from the validation of its factorial structure. As a result of our study, we slightly revised this module to an EORTC QLQ-FA12 phase IV version. We used confirmatory factor analysis to validate the a priori three-dimensional structure of EORTC QLQ-FA13 in conjunction with the two single items assessing the interference of CrF as criteria. The results show that the previous phase III module EORTC QLQ-FA13 did not reach a sufficient model fit for all items and therefore had to be modified. The changes include the elimination of a single item (FA11) and the allocation of one item (FA05) to the physical dimension instead of the cognitive dimension. The intercorrelation of FA11 within the factorial structure shows that this item may be not sufficiently understood as part of the cognitive dimension. In addition, item FA11 did not allow a clear allocation to the three dimensions and shows low factor loading for all three factors of 0.35 or less. As there is only a minor loss of information, we decided to eliminate this item. The allocation of item FA05 to the physical dimension improved the model fit substantially. In total, by these changes the model could be improved and we attained very good scores for the model fit. A cross-validation of the data and the replication of the model for the t2 and t3 measurements confirmed the results of the revised model. In terms of convergent and divergent validity, all coefficients for the model fit showed very good to excellent fit. Although the model fit decreases slightly over time, the fit measures are satisfactory or good for all points of measurement and overall much better than for the original model at t1. In accordance with these results, acceptable to very good scores for the internal reliability of the subscales (Cronbachs a from .79 to .90) were found.
The single item FA12 was predicted by the physical dimension, and the item FA13 by the cognitive dimension. These results are in line with the model assumptions, although we expected that these two items depended on all three dimensions. High correlations between the subscales of the revised EORTC FA12 with sociodemographic or medical parameters confirmed the convergent validity and are in line with the research literature (2, 3, 6, 18, 19) .
As in quality of life trials users often want to have a global scale of overall fatigue, we also calculated a second-order model of global fatigue. Here, various analyses showed that the assumption of an underlying overall fatigue construct has to be rejected. These results are in line with the underlying multidimensional concept of EORTC FA12, which means that emotional, cognitive, and physical aspects of CrF are not determined by a general underlying fatigue construct.
Analysis of test-retest reliability was conducted in two groups of cancer survivors, both off treatment. The results reveal a high correlation for all fatigue scores between t1 CD and t2 CD . Because no changes of fatigue are expected in this time period (average time difference of nine days), this indicates a stable measurement of fatigue by the EORTC QLQ-FA12 over time.
Our study had some limitations. First, we could not achieve equal sample sizes for all cooperating countries as patient recruitment proceeded at different levels in the various centers. Furthermore, in the palliative group (group B), recruitment was more difficult and high dropout rates prevailed.
In conclusion, the EORTC QLQ-FA12 has been proven in its multidimensional scale structure and improved by slight modifications of the item construct mapping. EORTC FA12 is available as an internationally developed phase IV module to be used for measuring cancer-related fatigue in conjunction with the EORTC QLQ-C30. For complete validation of this module, there is still a need for the analysis of the sensitivity to change and the intercultural differences, which we will approach as the next steps. The module is currently available in the following languages: English, Dutch, German, Polish, Italian, French, Spanish, Swedish, Norwegian, Arabic, and Mandarin. It is available from the EORTC Quality of Life Department. ARTICLE
